ArticleThe Journal of allergy and clinical immunology2020
Progression of acute-to-chronic atopic dermatitis is associated with quantitative rather than qualitative changes in cytokine responses.
Article in The Journal of allergy and clinical immunology, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. It is linked to trial NCT05140239 (Effects of Abrocitinib Treatment of Moderate to Severe Atopic Dermatitis on Skin Barrier Function), which is not on this map. Cited by 115 papers, 3 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Effects of Abrocitinib Treatment of Moderate to Severe Atopic Dermatitis on Skin Barrier Function
Who cites it
115 citing papers in PubMed, 3 syntheses or guidelines pooled it, 199 citations in OpenAlex.
- Quercetin exhibits multi-target anti-allergic effects in animal models: a systematic review and meta-analysis of preclinical studies.Frontiers in pharmacology · 2025Pooled it
- European and multi-ancestry genome-wide association meta-analysis of atopic dermatitis highlights importance of systemic immune regulation.Nature communications · 2023Pooled it
- Associations between COVID-19 and skin conditions identified through epidemiology and genomic studies.The Journal of allergy and clinical immunology · 2021Pooled it
- Tralokinumab plus topical corticosteroids for the treatment of moderate-to-severe atopic dermatitis: results from the double-blind, randomized, multicentre, placebo-controlled phase III ECZTRA 3 trial.The British journal of dermatology · 2021Trial
- Mechanism of Gu-Ben-Hua-Shi (AESS) Formula Regulating Autophagy Through Hippo-YAP Pathway in Restoring the Skin Barrier in Atopic Dermatitis.Journal of cellular and molecular medicine · 2026Observational
- From Barrier Disruption and Immune Dysregulation to Targeted Therapies in Atopic Dermatitis.Clinical reviews in allergy & immunology · 2026Review
- Misregulation of T-box transcription factors drives BNP-NPR1 signalling underlying chronic itch.Nature communications · 2026Article
- Single-cell transcriptome reveals keratinocyte subclusters contributing to altered differentiation and inflammatory responses in atopic dermatitis.Nature communications · 2026Article
- Article
- Pathobiology of atopic dermatitis and association with disease severity after acute oral steroid treatment.The journal of allergy and clinical immunology. Global · 2026Article
- The dual balance of the cytokine network: key messengers of immune activation and triggers of cytokine storm.Biomarker research · 2026Review
- Lindera obtusiloba extract attenuates cytokine-mediated epidermal inflammation in keratinocytes and an MC903-induced AD-like mouse model.Scientific reports · 2026Article
- Atopic dermatitis.Nature reviews. Disease primers · 2026Review
- Assessing D-Squame as a Minimally Invasive Technique to Evaluate the Cutaneous Immune Response mRNA in a Dog Model of Canine Atopic Dermatitis.Veterinary dermatology · 2026Article
- Sexual Dimorphism in Allergic and Mast Cell-Associated Diseases.Clinical reviews in allergy & immunology · 2026Review
- A Triple-Hit Multi-Omics Framework for Psoriasis: Microbial Metabolic Remodeling and Immune Cell Methylome Signature Associated with an AMP-Dominant Lesional Program.Life (Basel, Switzerland) · 2026Article
- Dysbiosis in the Pathogenesis of Atopic Dermatitis.The Journal of dermatology · 2026Review
- singIST: An integrative method for comparative single-cell transcriptomics between disease models and humans.PLoS computational biology · 2026Article
- A causal glycerophospholipid-IL-18R1-CD9 axis connects lipid metabolism and T-cell activation in atopic dermatitis.Briefings in bioinformatics · 2026Article
- Identifying dendritic cell heterogeneity and potential risk genes in atopic dermatitis: integrative scRNA-seq, bulk RNA-seq analyses and experimental validation.Frontiers in medicine · 2026Article
55 more citing papers are in PubMed but not listed here.
Corrections and comments
- Commented on by
- Erratum issuedCorrigendum.2023
Authors and funding
23 authors at 5 institutions in 3 countries.
Funding
Abstract
backgroundAlthough multiple studies have assessed molecular changes in chronic atopic dermatitis (AD) lesions, little is known about the transition from acute to chronic disease stages, and the factors and mechanisms that shape chronic inflammatory activity.
objectivesWe sought to assess the global transcriptome changes that characterize the progression from acute to chronic stages of AD.
methodsWe analyzed transcriptome changes in paired nonlesional skin, acute and chronic AD lesions from 11 patients and 38 healthy controls by RNA-sequencing, and conducted in vivo and histological assays to evaluate findings.
resultsOur data demonstrate that approximately 74% of the genes dysregulated in acute lesions remain or are further dysregulated in chronic lesions, whereas only 34% of the genes dysregulated in chronic lesions are altered already in the acute stage. Nonlesional AD skin exhibited enrichment of TNF, T
conclusionsOur results show that the changes accompanying the transition from nonlesional to acute to chronic inflammation in AD are quantitative rather than qualitative, with chronic AD having heightened T
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.